Patients with advanced cancer of the esophagus or gastroesophageal junction esophageal usually have a poor prognosis and the current recommendations do not offer any specific treatment in this case.
Immunotherapy anti-PD1 would represent a new opportunity for these patients according to a placebo-controlled trial that was published in The Lancet.
IMMUNOTHERAPY REPRESENTS A NEW SOLUTION IN CANCERS OF THE ESOPHAGUS IN ADVANCED STAGE